Ann: Trading Halt, page-178

hi we got a mention in the SMH

cheers

10.06am
Mesoblast in halt as investors hold breath for news

By Emma Koehn
Investors in stem cell hopeful Mesoblast have been refreshing their screens for the past 12 hours, waiting for news on whether the company’s flagship product, Ryoncil, would be approved by the US Food and Drug Administration.
Mesoblast shares entered a trading halt on the New York Stock Exchange yesterday and the company announced just before the market open that they were entering a halt on the ASX too. The FDA had set an “action date” of September 30 to make a final call on whether the company’s treatment for steroid-refractory graft-versus-host disease would be approved for use.

Mesoblast is in a trading halt pending news from the FDA.
If Mesoblast gets the green light it would be the first time in US history that a stem cell product like Ryoncil came to market.
In a statement to the ASX, the company has said it intends to enter a halt until an announcement on the FDA’s review, which is now not expected until Monday October 5. It’s currently around 8pm Wednesday on the US east coast and the New York Stock Exchange is closed.
Given the previously outlined schedules, it’s possible the FDA has made its decision.
However, Mesoblast says it intends to stay in a halt until Monday morning, when it expects to be able to share the news